SEC Form 4 
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 	  
OMB APPROVAL
OMB Number:	3235-0287	
Estimated average burden	
hours per response:	0.5	

X	
	
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			
1. Name and Address of Reporting Person*
Casdin Capital, LLC	

(Last)	(First)	(Middle)	
1350 AVENUE OF THE AMERICAS	
SUITE 2600	

(Street) 
NEW YORK	NY	10019	

(City)	(State)	(Zip)	
	2. Issuer Name and Ticker or Trading Symbol 
Fulcrum Therapeutics, Inc. [ FULC ] 	5. Relationship of Reporting Person(s) to Issuer 
(Check all applicable) 
	Director	X	10% Owner	
	Officer (give title below)		Other (specify below)	

	3. Date of Earliest Transaction (Month/Day/Year)
07/22/2019 		
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) 
	Form filed by One Reporting Person	
X	Form filed by More than One Reporting Person	
	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	
1. Title of Security (Instr. 3) 	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8) 	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	7. Nature of Indirect Beneficial Ownership (Instr. 4) 	
			Code	V	Amount	(A) or (D)	Price				
Common Stock	07/22/2019		C		464,285	A	(1)	464,285	I	See footnote(2) 	
Common Stock	07/22/2019		P		125,000	A	$16 	589,285	I	See footnote(2) 	
Common Stock	07/22/2019		P		10,000	A	$14.4996 	599,285	I	See footnote(2) 	
Common Stock	07/22/2019		P		5,000	A	$14.4998 	604,285	I	See footnote(2) 	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities) 	
1. Title of Derivative Security (Instr. 3) 	2. Conversion or Exercise Price of Derivative Security 	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 	8. Price of Derivative Security (Instr. 5) 	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 	11. Nature of Indirect Beneficial Ownership (Instr. 4) 	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Series B Preferred Stock	(1)	07/22/2019		C			3,250,000	(1) 	(1) 	Common Stock	464,285	$0.00 	0	I	See footnote(2) 	
1. Name and Address of Reporting Person*
Casdin Capital, LLC	

(Last)	(First)	(Middle)	
1350 AVENUE OF THE AMERICAS	
SUITE 2600	

(Street) 
NEW YORK	NY	10019	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
Casdin Partners Master Fund, L.P.	

(Last)	(First)	(Middle)	
1350 AVENUE OF THE AMERICAS	
SUITE 2600	

(Street) 
NEW YORK	NY	10019	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
Casdin Partners GP, LLC	

(Last)	(First)	(Middle)	
1350 AVENUE OF THE AMERICAS	
SUITE 2600	

(Street) 
NEW YORK	NY	10019	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
Casdin Eli	

(Last)	(First)	(Middle)	
1350 AVENUE OF THE AMERICAS	
SUITE 2600	

(Street) 
NEW YORK	NY	10019	

(City)	(State)	(Zip)	
	
Explanation of Responses:	
1. On July 22, 2019, the Series B Preferred Stock converted into Common Stock on a seven-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.	
2. The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.	
	Casdin Partners Master Fund LP, By: Casdin Partners GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member	07/22/2019	
	Casdin Capital, LLC, By: /s/ Eli Casdin, Managing Member	07/22/2019	
	Casdin Partners GP LLC, By: /s/ Eli Casdin, Managing Member	07/22/2019	
	/s/ Eli Casdin	07/22/2019	
	** Signature of Reporting Person	Date	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).	
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.